Black Rock Inc. E Ffector Therapeutics, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.35 - $1.39 $18,382 - $73,005	-52,522 Reduced 98.96%	554 $0
Q1 2023 May 12, 2023	BUY	$0.35 - $0.67 $6,408 - $12,267	18,310 Added 52.67%	53,076 $18,000
Q4 2022 Feb 13, 2023	BUY	$0.38 - $0.66 $1,051 - $1,826	2,767 Added 8.65%	34,766 $14,000
Q3 2022 Nov 14, 2022	BUY	$0.08 - $1.41 $1,224 - $21,573	15,300 Added 91.62%	31,999 $18,000
Q2 2022 Aug 12, 2022	BUY	$1.3 - $3.84 $20,235 - $59,773	15,566 Added 1373.87%	16,699 $24,000
Q4 2021 Feb 10, 2022	BUY	$5.71 - $13.15 $6,469 - $14,898	1,133 New	1,133 $10,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.